May 19, 2021 5:00pm EDT Two Complete Responses and Response Rate of 41% for People with Synovial Sarcoma Reported at ASCO in Adaptimmune’s Phase 2 SPEARHEAD-1 Trial
May 11, 2021 8:00am EDT First Preclinical Data from Adaptimmune’s Mesothelin HiT Program at ASGCT Demonstrate Antigen-specific Tumor Cell Killing in vitro and Complete Tumor Regression in an Animal Model
Apr 27, 2021 4:30pm EDT Adaptimmune to Present First Preclinical Data from its HLA-independent TCR (HiT) Platform at ASGCT
Apr 22, 2021 8:00am EDT Adaptimmune to Report Q1 2021 Financial Results and Business Update on Thursday, May 6, 2021
Feb 25, 2021 7:30am EST Adaptimmune Reports Fourth Quarter / Full Year 2020 Financial Results and Business Update
Feb 11, 2021 8:00am EST Adaptimmune to Report Fourth Quarter/ Full Year 2020 Financial Results and Business Updates on Thursday, February 25, 2021
Nov 20, 2020 7:30am EST Adaptimmune to Showcase Market Potential for SPEAR T-cell Portfolio and Pipeline with Multiple Cell Therapy Platforms During Virtual Investor Day
Nov 19, 2020 9:00am EST Durable Responses with ADP-A2M4 in Synovial Sarcoma with Confirmed Responses in 44% of Patients and Disease Control Rate of 94% Presented at CTOS
